Dr. Alex Colville joins forces with Laura Deming to lead investments in longevity science moonshots, after deploying $100M fund last year while at Stanford
age1, a venture capital firm catalyzing ...
Inceptive’s Jakob Uszkoreit, a pioneer of the technology behind ChatGPT, attracts Nvidia funding to design ‘biological software’.
A biotech start-up founded by a former Google artificial intelligence expert has raised ...
Jakob Uszkoreit, one of the people who laid the groundwork for generative platforms such as ChatGPT, has secured $100 million in a Series A raise for an AI biotech ...
Chronic diseases like cancer, heart disease and diabetes, first hit the average American in their 60s. Cancer is usually diagnosed at 66, the average age for a first heart attack in ...
Scientists obsessed with aging are sketching a road map of how our bodies change as we grow old in the hopes that it will lead to treatments that could ...
The Atlantic celebrates science, tech, and a culture of curiosity.
Join us to explore how innovation borrows from unexpected corners, featuring Airbnb’s Brian Chesky, Google DeepMind’s Pushmeet Kohli, Anthropic’s Dario ...
Scientists are engineering microbes to make healthier compounds. They hope they’ll help treat disease and save the planet.
Microbes have been on my mind this week. These tiny organisms are ...
Hype springs eternal in medicine, but lately the horizon of new possibility seems almost blindingly bright. “I’ve been running my research lab for almost 30 years,” says Jennifer Doudna, ...
CRISPR pioneer Jennifer Doudna's company Scribe Therapeutics inked a major deal with Prevail Therapeutics potentially worth $1.5 billion to create genetic medicines for neurological and neuromuscular diseases. Scribe CEO ...
Scribe Therapeutics found another partner, this time with Prevail Therapeutics, a subsidiary of Eli Lilly, in a $75 million upfront deal for neuromuscular and neurological diseases.
Unlike Scribe’s ex vivo ...
Collaboration combines Scribe Therapeutics’ novel CRISPR by Design™ approach with Prevail Therapeutics’ deep expertise in developing genetic medicines for neurological disorders towards specified genetic targets
Scribe to receive ...
The times are changing in biopharma.
With the top drugmakers no longer committing most of their resources to the pandemic, biopharma is returning to its roots. But it’s clear the ...
Deep in the bellies of cows are tiny microbes that ferment grass and hay, breaking it down into fatty acids that serve as bovine energy—and into planet-warming methane gas. ...
When a startup called Retro Biosciences eased out of stealth mode in mid-2022, it announced it had secured $180 million to bankroll an audacious mission: to add 10 years to ...
As a postdoctoral researcher at Stanford University, Kristen Fortney used bioinformatics to study the genetics of supercentenarians — people who live to the age of 110 and beyond. Now ...
We sat down with some of the most curious minds in life sciences and healthcare and invited them to share their thoughts on their careers, the future of health ...
“Why is it in popular culture, if you want to live forever, you are evil and you want to kill babies on the side?” says Martin Borch Jensen.
It’s fast ...
Tech billionaires are funding research to help us live longer and healthier lives, but experts warn of an ethical minefield ahead.
When Nir Barzilai specialised in anti-ageing science 30 years ...
Scientists are great at making mice live longer.
Rapamycin, widely prescribed to prevent organ rejection after a transplant, increases the life expectancy of middle-age mice by as much as 60 ...
The parents of a 2-year-old girl write that their daughter “could die within the next year” because a genetic mutation is causing her heart to fail.
“Time is quickly running ...
A guide to contemporary doomsday scenarios — from the threats you know about to the ones you never think of.
And here we are at the crux of our existential ...
The 2020 Nobel Laureate shares her thoughts on the first decade of CRISPR genome editing, where the technology is heading next, and what it needs to get there.
Last month, Genetic ...
Research labs are pursuing technology to “reprogram” aging bodies back to youth.
A little over 15 years ago, scientists at Kyoto University in Japan made a remarkable discovery. When they ...
Sanofi has teamed up with Scribe Therapeutics to write the next chapter in its natural killer (NK) cell therapy story, paying $25 million upfront and committing to $1 billion ...
Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, today announced a strategic collaboration with Sanofi for the use of Scribe’s CRISPR ...
It’s entirely possible, maybe even likely, that during some slow day at the lab early in her career, Jennifer Doudna, in a moment of private ambition, daydreamed about making ...
“CRISPR-by-design” is the idea behind Scribe Therapeutics, a company spun out from Jennifer Doudna’s Nobel-winning lab that’s competing in a closely-tracked field of genome editor companies just starting to ...
Cartography Biosciences, a precision medicine company creating therapeutics guided by the first-ever comprehensive antigen atlas for immuno-oncology targets, launched today with $57 million in initial funding. 8VC led the ...
Jennifer Doudna was staring at a computer screen filled with a string of As, Cs, Ts, and Gs—the letters that make up human DNA—and witnessing a debilitating genetic disease ...
On June 28, 2012, a joint press release went out from the U.S. Department of Energy and the Lawrence Berkeley National Laboratory announcing a new paper in Science from an ...
The gene-editing tool has transformed the study of human disease, but before it can revolutionize treatments, researchers will need to solve three basic problems.
Ten years ago this week, a report of ...
The gene-editing technology has led to innovations in medicine, evolution and agriculture — and raised profound ethical questions about altering human DNA.
Ten years ago this week, Jennifer Doudna and ...
New funding from the Chan Zuckerberg Initiative kickstarts CRISPR-enabled carbon removal research at the Innovative Genomics Institute
A new research program at the Innovative Genomics Institute (IGI), supported by a ...
LatchBio, a company accelerating the pace of scientific progress by enabling researchers to store and analyze data without touching code or cloud infrastructure, today announced a $28 million Series ...
Innovative Genomics Institute Founder, Nobel Laureate, and CRISPR co-discoverer Jennifer Doudna joins Emily Chang to discuss the future of the CRISPR technology and its commercialization, as well as the ...
Sixth Street Chief Science Adviser and Nobel laureate Jennifer Doudna, co-founder of the CRISPR genome editing technology, and Sixth Street Vice Chairman and Partner R. Martin Chavez join Emily ...
Every second of every day inside your body, proteins are made, moved, modified, and destroyed over and over again. These proteins can be short strings of amino acids or ...
Benjamin Oakes is carving out a space in the gene-editing field by developing what he calls a "genetic scalpel."
After researching gene editing in the labs of CRISPR pioneer Jennifer ...
CRISPR is the latest and most powerful technique for changing the genetic code of living things. This method of gene editing is already showing great promise in treating people ...
Gene editing has become one of biotech's hottest areas as the first-in-human results have suggested the technology holds the potential to cure certain diseases with a single treatment.
In 2021, ...
Last year, Jennifer Doudna and Emmanuelle Charpentier became the first all-woman team to win the Nobel Prize in Chemistry for their work developing CRISPR-Cas9, the gene-editing technology. The technology ...
Proteins are the building blocks of the human body and have many critical roles. Since proteins are involved in multiple biological functions, they also play an important role in ...
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the completion of its business combination with Arya Sciences Acquisition Corp III ...
Digital data related to Nobel Prize-winning inventions for gene editing and cancer immunotherapy will be sold connected to non-fungible tokens next week, a novel way for the University of ...
Developing therapeutics is difficult—developing neurotherapeutics is even harder. The blood-brain barrier protecting the brain from unwanted substances makes it extremely difficult for neurotherapeutics to reach their target.
Herophilus, a San ...
How much will someone be willing to pay for a few pages of quarter-century-old bureaucratic university paperwork that have been turned into a blockchain-encoded piece of digital art?
Berkeley announced ...
Herophilus, a leading biotechnology company developing neurotherapeutics to cure complex brain diseases, has appointed Sharath Hegde, Ph.D. as the company’s new Chief Scientific Officer. Dr. Hegde brings over 30 ...
Ben Oakes’ dive inside the human mind colors his leadership role at gene editing startup Scribe Therapeutics.
As an undergrad, Ben Oakes wanted to learn how the mind worked — ...
Scribe Therapeutics is adding another $100 million to its coffers six months after unveiling a $20 million series A and a partnership with Biogen to work on gene editing ...
Scribe Therapeutics has completed an oversubscribed $100-million Series B financing, with aims to further develop its suite of custom gene-editing and delivery technologies based on molecular engineering, as well ...
Nearly a decade ago, when the first CRISPR companies started looking for capital, Behzad Aghazadeh passed.
Aghazadeh, one of biotech’s more opinionated investors, had invested in gene editing before, but ...
Imagine being able to change the genes responsible for causing diseases. For Scribe Therapeutics, a gene-editing company that develops genetic medicines, this is no longer a dream but a ...
When last year’s Nobel prize for chemistry was awarded to biochemist Jennifer Doudna and microbiologist Emmanuelle Charpentier for their work in developing the technique of gene editing known as Crispr-Cas9 ...
In the spring of 2014, Jennifer Doudna had a nightmare.
The Berkeley biochemist had helped to invent a powerful new technology that made it possible to edit the human genome—an ...
In The Code Breaker, Walter Isaacson recounts the drama of the discovery in a digestible narrative that tackles the promise and the peril of Crispr.
For Isaacson, an accomplished storyteller of ...
In February, Jennifer Doudna, one of America’s most prominent scientists, was still focused on CRISPR—the gene-editing tool that she’d co-discovered and that won her a Nobel Prize in October. But ...
When Jennifer Doudna woke up, she realised her phone had been buzzing on and off for some time. It was still dark outside. In fact, her phone told her ...
